Company news

Travere Therapeutics, Inc. news in 2026

Travere Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 12, 2026

Travere Therapeutics to Participate at Upcoming Investor Conferences

November 3, 2026

Travere Therapeutics Reports Third Quarter 2026 Financial Results

November 2, 2026

Travere Therapeutics to Report Third Quarter 2026 Financial Results

October 26, 2026

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

October 23, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 12, 2026

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

October 2, 2026

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

September 23, 2026

Travere Therapeutics Announces Planned Chief Executive Officer Transition

September 21, 2026

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

September 17, 2026

Travere Therapeutics Reports Second Quarter 2026 Financial Results

August 4, 2026

Travere Therapeutics to Report Second Quarter 2026 Financial Results

July 28, 2026

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

June 16, 2026

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

June 3, 2026

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

June 2, 2026

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

May 27, 2026

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

May 6, 2026

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

May 5, 2026

Travere Therapeutics Reports First Quarter 2026 Financial Results

May 3, 2026

Travere Therapeutics to Report First Quarter 2026 Financial Results

April 27, 2026

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS

April 12, 2026

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

February 19, 2026

Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

February 4, 2026

Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

January 13, 2026

Travere Therapeutics Provides Corporate Update and 2026 Outlook

January 11, 2026

Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026